MSB · ASX

Mesoblast Limited (ASX:MSB)

AU$2.54

 0.14 (5.833%)
ASX:Live
02/10/2025 04:10:16 PM
HALO Small HALO Ords HALO 200 GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

MSB Overview

MSB Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Very Weak

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Neutral

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Weak

Balance Sheet

Very Weak

About MSB

Website

Mesoblast Limited

Telephone

61.3.9639.6036

Address

Level 38 55 Collins Street Melbourne, Victoria (VIC) 3000

Description

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

MSB Price Chart

Key Stats

Market Cap

AU$3.07B

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.18 - 3.37

Trade Value (12mth)

US$2,203,260.00

1 week

0%

1 month

18.81%

YTD

-28.36%

1 year

92.77%

All time high

9.42

Key Fundamentals

EPS 3 yr Growth

-36.60%

EBITDA Margin

-326.40%

Operating Cashflow

-$57m

Free Cash Flow Return

-9.20%

ROIC

-16.70%

Interest Coverage

-2.40

Quick Ratio

1.80

Other Data

Shares on Issue (Fully Dilluted)

1272m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

USD

Short Sell (% of issue)

8.16

MSB Announcements

Latest Announcements

Date Announcements

26 September 25

Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs

×

Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs

22 September 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

16 September 25

Becoming a substantial holder

×

Becoming a substantial holder

16 September 25

Becoming a substantial holder

×

Becoming a substantial holder

15 September 25

Ryoncil Launch Highlighted at Global Healthcare Conferences

×

Ryoncil Launch Highlighted at Global Healthcare Conferences

15 September 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

12 September 25

Change in substantial holding

×

Change in substantial holding

12 September 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

04 September 25

Mesoblast Option to Issue up to US$50m Convertible Notes

×

Mesoblast Option to Issue up to US$50m Convertible Notes

04 September 25

Proposed issue of securities - MSB

×

Proposed issue of securities - MSB

29 August 25

Preliminary Final Report including Appendix 4E

×

Preliminary Final Report including Appendix 4E

29 August 25

Annual Financial Results Presentation

×

Annual Financial Results Presentation

29 August 25

MSB Annual Financial Results and Operational Update

×

MSB Annual Financial Results and Operational Update

29 August 25

Becoming a substantial holder

×

Becoming a substantial holder

27 August 25

Mesoblast 2025 Full Year Financial Results Webcast

×

Mesoblast 2025 Full Year Financial Results Webcast

25 August 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

29 July 25

Becoming a substantial holder

×

Becoming a substantial holder

25 July 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

25 July 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

23 July 25

Becoming a substantial holder

×

Becoming a substantial holder

21 July 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

18 July 25

Becoming a substantial holder

×

Becoming a substantial holder

18 July 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

14 July 25

Notification regarding unquoted securities - MSB

×

Notification regarding unquoted securities - MSB

14 July 25

Application for quotation of securities - MSB

×

Application for quotation of securities - MSB

MSB Fundamentals

Per Share Records

Historical data

Forecast data

USD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.11 -0.09 -0.08 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.11 -0.09 -0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.3 15.2 5.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.08 -0.05 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.09 -0.06 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock 30.5 40.2 10.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -12.3 -8.7 -4.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.58 0.42 0.47 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock -0.09 -0.08 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 26.3 4.8 123.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 779 987 1,208 Lock Lock Lock
Basic m Lock Lock Lock Lock 779 987 1,208 Lock Lock Lock

Financial Records

Historical data

Forecast data

USD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 8 6 17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.5 -21.3 191.4 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 53 49 68 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -20 -10 6 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.5 51.5 157.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -269.7 -166.3 33.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 370 266 67 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -69 -54 -56 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.8 21.1 -3.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -915.7 -917.7 -326.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 4 5 6 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -73 -59 -63 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.7 19.2 -6.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -970.5 -996.8 -363.6 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -86 -89 -102 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -4 -1 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -82 -88 -102 Lock Lock Lock
     Growth % Lock Lock Lock Lock 10.4 -7.4 -16.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,091.7 -1,490.3 -593.9 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -69 -56 -57 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 81 48 154 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -70 -56 -57 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.4 19.5 -2.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -9.3 -9.5 -3.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 71 63 162 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 669 669 785 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 106 102 71 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 45 56 -33 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 168 189 187 Lock Lock Lock
Equity $m Lock Lock Lock Lock 507 471 590 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 608 583 669 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.1 -4.2 14.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -12.2 -13.1 -13.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -16.1 -18.7 -17.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -12.0 -9.8 -9.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -13.7 -15.0 -16.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -11.6 -9.5 -9.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

USD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock -3.4 -2.4 -2.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -0.7 -1.0 0.6 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 8.9 11.9 -5.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.9 1.2 2.0 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.9 1.2 1.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 87.3 72.8 79.1 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -165.0 -76.1 -55.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 1.3 0.4 1.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 1.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.2 0.5 0.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 271.4 117.5 109.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,141.3 -1,508.1 -592.5 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -12.8 -13.3 -13.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -12.2 -13.1 -13.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 1.4 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -16.1 -18.7 -17.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -16.1 -18.7 -17.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 348.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 276.8 848.7 371.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 276.8 848.7 719.5 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 282.5 310.8 140.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -5.7 537.9 579.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

6.63%

Value ($M)

211

Prior Change

N/A

7 Day Change

0.10%

1 Month Change

1.00%

3 Month Change

0.30%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

MSB Shortsell

Frequently Asked Questions

The current share price of Mesoblast Limited (MSB:ASX) is AU$2.54.
The 52-week high share price for Mesoblast Limited (MSB:ASX) is AU$3.37.
The 52-week low share price for Mesoblast Limited (MSB:ASX)? is AU$1.18.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) has a franking level of 0.0%.
Mesoblast Limited (MSB:ASX) is classified in the Healthcare.
The current P/E ratio for Mesoblast Limited (MSB:ASX) is .
The current share price of Mesoblast Limited (MSB:ASX) is AU$2.54.
The 52-week high share price for Mesoblast Limited (MSB:ASX) is AU$3.37.
The 52-week low share price for Mesoblast Limited (MSB:ASX)? is AU$1.18.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) has a franking level of 0.0%.
Mesoblast Limited (MSB:ASX) is classified in the Healthcare.
The current P/E ratio for Mesoblast Limited (MSB:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox
App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

Ff